← Back to Screener
Emergent Biosolutions, Inc. (EBS)
Price$8.62
Favorite Metrics
Price vs S&P 500 (26W)-16.42%
Price vs S&P 500 (4W)2.43%
Market Capitalization$438.98M
P/E Ratio (Annual)8.35x
All Metrics
P/CF (Annual)2.57x
Book Value / Share (Quarterly)$10.03
P/TBV (Annual)7.54x
Revenue Growth (3Y)-12.81%
Cash Flow / Share (Quarterly)$3.01
Price vs S&P 500 (YTD)-32.58%
Gross Margin (TTM)56.23%
Net Profit Margin (TTM)7.08%
EPS (TTM)$0.83
10-Day Avg Trading Volume0.71M
EPS Excl Extra (TTM)$0.83
Revenue Growth (5Y)-13.74%
EPS (Annual)$0.93
ROI (Annual)4.80%
Gross Margin (Annual)56.09%
Net Profit Margin (5Y Avg)-18.06%
Cash / Share (Quarterly)$3.94
P/E Basic Excl Extra (TTM)8.35x
Revenue Growth QoQ (YoY)-23.63%
EPS Growth (5Y)-30.38%
P/E Normalized (Annual)8.35x
ROA (Last FY)3.99%
Revenue Growth TTM (YoY)-28.81%
EBITD / Share (TTM)$3.76
ROE (5Y Avg)-29.65%
Operating Margin (TTM)13.47%
Cash Flow / Share (Annual)$3.01
P/B Ratio0.84x
P/B Ratio (Quarterly)1.24x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.08x
Net Interest Coverage (TTM)2.40x
ROA (TTM)3.74%
EPS Growth QoQ (YoY)-56.11%
EV / EBITDA (TTM)3.89x
EPS Incl Extra (Annual)$0.93
Current Ratio (Annual)5.01x
Quick Ratio (Quarterly)2.22x
3-Month Avg Trading Volume0.90M
52-Week Price Return89.08%
EV / Free Cash Flow (Annual)5.14x
P/E Incl Extra (TTM)8.35x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.65
P/S Ratio (Annual)0.59x
Asset Turnover (Annual)0.56x
52-Week High$14.06
Operating Margin (5Y Avg)-10.91%
EPS Excl Extra (Annual)$0.93
CapEx CAGR (5Y)-38.03%
Tangible BV CAGR (5Y)-24.31%
26-Week Price Return-12.44%
Quick Ratio (Annual)2.22x
13-Week Price Return-30.10%
Total Debt / Equity (Annual)1.09x
Current Ratio (Quarterly)5.01x
Enterprise Value$805.683
Revenue / Share Growth (5Y)-14.64%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)-18.12%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.00x
Pretax Margin (Annual)11.15%
Cash / Share (Annual)$3.94
3-Month Return Std Dev74.00%
Gross Margin (5Y Avg)43.73%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-16.10%
EBITDA Interim CAGR (5Y)2.80%
ROE (Last FY)10.07%
Net Interest Coverage (Annual)2.40x
EPS Basic Excl Extra (Annual)$0.93
P/FCF (TTM)2.48x
Receivables Turnover (TTM)6.22x
EV / Free Cash Flow (TTM)5.14x
Total Debt / Equity (Quarterly)1.09x
EPS Incl Extra (TTM)$0.83
Receivables Turnover (Annual)6.22x
ROI (TTM)4.42%
P/S Ratio (TTM)0.59x
Pretax Margin (5Y Avg)-14.97%
Revenue / Share (Annual)$13.10
Tangible BV / Share (Annual)$1.65
Forward P/E16.58x
Free OCF CAGR (5Y)-16.44%
Price vs S&P 500 (52W)59.25%
P/E Ratio (TTM)8.35x
Year-to-Date Return-29.94%
5-Day Price Return2.49%
EPS Normalized (Annual)$0.93
ROA (5Y Avg)-10.14%
Net Profit Margin (Annual)7.08%
Month-to-Date Return4.34%
Cash Flow / Share (TTM)$-9.38
EBITD / Share (Annual)$3.65
Operating Margin (Annual)11.83%
LT Debt / Equity (Annual)1.09x
P/CF (TTM)2.57x
ROI (5Y Avg)-12.17%
P/E Excl Extra (TTM)8.35x
LT Debt / Equity (Quarterly)1.09x
EPS Basic Excl Extra (TTM)$0.83
P/TBV (Quarterly)7.54x
P/B Ratio (Annual)1.24x
Inventory Turnover (TTM)0.99x
Pretax Margin (TTM)11.15%
Book Value / Share (Annual)$10.03
Price vs S&P 500 (13W)-30.79%
Net Margin Growth (5Y)-18.44%
Beta2.50x
P/FCF (Annual)2.80x
Revenue / Share (TTM)$14.20
ROE (TTM)9.59%
52-Week Low$4.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EBSEmergent Biosolutions, Inc. | 0.59x | -28.81% | 56.23% | -30.38% | $8.62 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Emergent BioSolutions develops and manufactures pharmaceutical products and medical countermeasures for public health markets. The company operates three main segments: commercial respiratory products including NARCAN and KLOXXADO nasal sprays; government-contracted medical countermeasures such as anthrax and smallpox vaccines; and bioservices. Revenue is primarily derived from the U.S. market.